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Abstract
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal
pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line
therapeutics for Candida infections. Here, we provide the first global analysis of mutations accompanying the evolution of
fungal drug resistance in a human host utilizing a series of C. glabrata isolates that evolved echinocandin resistance in a
patient treated with the echinocandin caspofungin for recurring bloodstream candidemia. Whole genome sequencing
identified a mutation in the drug target, FKS2, accompanying a major resistance increase, and 8 additional non-synonymous
mutations. The FKS2-T1987C mutation was sufficient for echinocandin resistance, and associated with a fitness cost that was
mitigated with further evolution, observed in vitro and in a murine model of systemic candidemia. A CDC6-A511G(K171E)
mutation acquired before FKS2-T1987C(S663P), conferred a small resistance increase. Elevated dosage of CDC55, which
acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated fitness. To discover strategies to abrogate
echinocandin resistance, we focused on the molecular chaperone Hsp90 and downstream effector calcineurin. Genetic or
pharmacological compromise of Hsp90 or calcineurin function reduced basal tolerance and resistance. Hsp90 and
calcineurin were required for caspofungin-dependent FKS2 induction, providing a mechanism governing echinocandin
resistance. A mitochondrial respiration-defective petite mutant in the series revealed that the petite phenotype does not
confer echinocandin resistance, but renders strains refractory to synergy between echinocandins and Hsp90 or calcineurin
inhibitors. The kidneys of mice infected with the petite mutant were sterile, while those infected with the HSP90-repressible
strain had reduced fungal burden. We provide the first global view of mutations accompanying the evolution of fungal drug
resistance in a human host, implicate the premier compensatory mutation mitigating the cost of echinocandin resistance,
and suggest a new mechanism of echinocandin resistance with broad therapeutic potential.
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Introduction
The emergence of drug resistance is an evolutionary process
with a profound impact on human health. The widespread
deployment of antimicrobial agents in medicine and agriculture
exerts strong selection for organisms with enhanced capacity to
survive and reproduce in the presence of drug, which has led to the
rapid emergence of drug resistance in diverse pathogen popula-
tions [1–4]. The evolution of drug resistance compromises the
efficacy of drugs that we depend on critically for a myriad of
therapeutic interventions, and has striking economic consequenc-
es. The annual cost attributable to the evolution of drug resistance
in the United States alone exceeds $33 billion to cover treatment
of patients with drug-resistant infections, additional pesticides
required to manage resistant pests, and loss of crops to resistant
pests [5]. The emergence of drug resistance in fungal pathogens is
of particular concern given the increasing incidence of invasive
fungal infections, and the limited number of antifungal drugs.
Fungi can cause life-threatening infectious disease in immuno-
compromised hosts, as well as in healthy humans, and the
incidence of fungal bloodstream infections has increased by 207%
in recent decades [6–8]. Fungi are eukaryotes and share close
evolutionary relationships with their human hosts, which limits the
number of drug targets that can be exploited to selectively kill
fungal pathogens yet minimize host toxicity [1,3]. Even with
current treatment options, mortality rates due to invasive fungal
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002718infections can reach 50–90% depending on the pathogen and
patient population [7,8], demanding new strategies to prevent the
evolution of drug resistance and enhance the efficacy of antifungal
drugs.
The evolution of drug resistance is contingent on genetic
variability, the ultimate source of which is mutation. One of the
most fundamental questions of central importance to predicting
and preventing the evolution of drug resistance is which mutations
accompany the evolution of drug resistance in the human host.
Developments in sequencing technology [9–11] now enable this
question to be addressed on a genome-wide scale to reveal the
identity of mutations that either confer drug resistance in a
clinically relevant context or that modify the fitness consequences
of resistance mutations. Whole genome sequencing has been
applied to bacteria and has revealed principles underpinning the
evolution and transmission of drug-resistant pathogens [12], risk
factors for the evolution of drug resistance [13], and population
dynamics during the evolution of drug resistance in vitro [14]. In
fungi, changes in genome-wide gene expression and chromosomal
alterations that accompany the evolution of drug resistance have
been monitored in experimental populations that evolved resis-
tance in vitro [15,16], and targeted sequence and expression
analysis of specific genes has been implemented to identify
mechanisms of resistance that evolve in the human host [1,17].
However, a global approach to mapping mutations that underpin
the evolution of fungal drug resistance has yet to be achieved.
Candida glabrata is a leading fungal pathogens of humans and
provides a particularly powerful system for studying the evolution
of drug resistance in a human host. Candida species are the fourth
most common cause of hospital acquired blood-stream infections
and are the most prevalent cause of invasive fungal infection
worldwide, with mortality rates approaching 50% [7,18]. C.
glabrata is now second to C. albicans as the most prevalent Candida
species isolated from clinical specimens [7,8,19]. This is due in
part to both intrinsic and rapidly acquired resistance of C. glabrata
to the azoles, which are the most widely used class of antifungal
drugs and inhibit the biosynthesis of the key sterol in fungal cell
membranes, ergosterol [20]. As a consequence, the echinocandins
are the front-line therapeutic agent for C. glabrata infections [19].
C. glabrata is closely related to the model yeast Saccharomyces cerevisiae
and is placed within the Saccharomyces clade rather than the Candida
clade to which the leading cause of candidiasis, C. albicans, belongs
[21–23]. It is thought that C. glabrata emerged as a human
pathogen independently from other Candida species. Notably, gene
families associated with pathogenicity in C. albicans including iron
acquisition and host cell adhesion and invasion are absent from C.
glabrata [24]. C. glabrata is an obligate haploid and mating has never
been reported, although two mating types, mating type switching,
and other mating and meiotic machinery have been described
[25–27]. To increase genetic diversity C. glabrata undergoes
chromosomal translocations and variation in gene copy number
[28,29], mechanisms that also contribute to C. albicans resistance to
azoles [16,30,31]. As a haploid, analysis of C. glabrata genome
sequence is more facile than in diploids such as C. albicans, where
mitotic recombination and gene conversion can inflate the number
of polymorphisms that accrue and obscure the signal of those
functionally associated with drug resistance or adaptation to the
host.
Compared to the most widely used antifungal drugs in clinical
use for the treatment of systemic infections, the azoles, mecha-
nisms of resistance remain more limited for echinocandins. The
echinocandins are the only novel class of antifungal drugs
approved for clinical use in decades and target the biosynthesis
of the key fungal cell wall component, 1,3-b-D-glucan [3,20,32].
The 1,3-b-D-glucan synthases are encoded by FKS1, FKS2, and
FKS3 in S. cerevisiae, C. glabrata, and C. albicans, and require a
regulatory subunit encoded by RHO1 for activity [3,20,32,33]. It is
thought that the echinocandins bind to and inhibit the Fks protein;
however, the exact mechanism of inhibition remains unknown
[33]. Although the echinocandins have been in clinical use since
only 2001, there have been numerous reports of C. glabrata
echinocandin resistance in patients [34–37]. Thus far, the only
echinocandin resistance mechanism described is mutation in the
drug target, Fks, particularly in highly conserved hot spots regions
[33,36–39]. Such mutations can reduce echinocandin susceptibil-
ity of 1,3-b-D-glucan synthase by 2 to 3 log orders relative to the
wild-type enzyme [36]. Additional resistance mechanisms may
remain to be described given that Fks mutations have not been
identified in some echinocandin-resistant isolates [20,37,40], and
that isolates with identical Fks mutations exhibit different
resistance phenotypes with distinct responses to cellular perturba-
tions [41]. Even with azoles, for which resistance mechanisms have
been studied for decades, new resistance mechanisms and
modulators of resistance continue to be discovered, expanding
the repertoire of strategies employed by fungi to survive drug
exposure to include mutation in the drug target, overexpression of
multidrug-efflux transporters, and metabolic alterations that
minimize drug toxicity [3,20,32]. In addition to these canonical
resistance mechanisms where mutations in relevant genes confer
resistance, there is also an emergent paradigm in which regulators
of cellular stress responses are crucial for enabling the evolution
and maintenance of drug resistance [3,20,32]; while mutations in
these regulators have not been identified as a cause of resistance,
stress response regulators are key resistance modulators critical for
enabling the phenotypic effects of resistance acquired by diverse
mechanisms.
Beyond mapping mutations that confer resistance, there is
pressing clinical need to elucidate strategies to block the evolution
of drug resistance and abrogate resistance once it has evolved. One
of the most well studied examples of a protein that governs the
emergence and maintenance of fungal drug resistance is the
molecular chaperone Hsp90. Hsp90 regulates the folding and
Author Summary
The evolution of drug resistance poses a severe threat to
human health. Candida glabrata is a leading cause of
mortality due to fungal infections worldwide. It can rapidly
evolve resistance to drugs such as echinocandins, which
target the fungal cell wall and are front-line therapeutics
for Candida infections. We harness whole genome
sequencing to provide a global view of mutations that
accumulate in C. glabrata during the evolution of
echinocandin resistance in a human host. Nine non-
synonymous mutations were identified, including one in
the echinocandin target. A mutation in an additional gene
conferred a small resistance increase and another was in a
gene whose dosage mitigated the fitness cost of
resistance. We further discovered that compromising
function of the molecular chaperone Hsp90 abrogates
drug resistance and reduces kidney fungal burden in a
mouse model of infection. Hsp90 and its downstream
effector calcineurin are required for induction of the drug
target in response to drug. Thus, we reveal the first global
portrait of antifungal resistance mutations that evolve in a
human host, identify the first compensatory mutation that
mitigates the cost of echinocandin resistance, and suggest
a new mechanism of echinocandin resistance that can be
exploited to treat life-threatening fungal infections.
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transducers [42,43]. In C. albicans, compromise of Hsp90 function
reduces basal tolerance and resistance of clinical isolates to both
the azoles and the echinocandins [41,44,45]. Hsp90 enables
crucial responses to drug-induced stress by orchestrating signaling
through the protein phosphatase calcineurin and the protein
kinase C (PKC) cell wall integrity signaling cascade [41,46]. Hsp90
stabilizes the catalytic subunit of calcineurin and the terminal
mitogen-activated protein kinase (MAPK) in the Pkc1 cell wall
integrity pathway. Genetic or pharmacological compromise of
Hsp90 function can enhance the efficacy of antifungals against C.
albicans in multiple metazoan models of infection [41,45]. Notably,
Hsp90’s role in governing cellular responses to azoles in C. albicans
is conserved in S. cerevisiae [44,47]. In contrast, Hsp90 and
calcineurin play a key role in crucial cellular responses to
echinocandins in C. albicans, but not in S. cerevisiae [41]. Whether
Hsp90 influences drug resistance in C. glabrata remains entirely
unknown. In C. glabrata, both calcineurin and PKC signaling have
been implicated in basal tolerance to echinocandins [48,49],
though the role of Hsp90 remains unknown as does the impact of
any of these regulators on bona fide echinocandin resistance.
Here, we provide the first global analysis of mutations
accompanying the evolution of fungal drug resistance in a human
host. We report on a series of C. glabrata isolates that evolved
echinocandin resistance in a patient undergoing treatment with
the echinocandin caspofungin for recurring C. glabrata candidemia
over a 10-month period. Whole genome sequencing revealed that
a mutation occurred in the gene encoding the drug target, FKS2,
accompanying a major increase in resistance, as well as 8 other
non-synonymous mutations in genes not previously implicated in
echinocandin resistance, including CDC6 and CDC55. The FKS2-
T1987C(S663P) mutation was sufficient to confer echinocandin
resistance in a susceptible laboratory strain; however, the mutant
allele also imparted a growth defect in clinically relevant
conditions using RPMI medium at 37uC. The fitness cost of
resistance was mitigated with further evolution, and this trend was
also observed in a murine model of disseminated infection. A
CDC6-A511G (K171E) mutation acquired prior to the FKS2-
T1987C(S663P) mutation was sufficient to confer a small increase
in resistance. Elevated dosage of CDC55, which acquired a
C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated
the fitness cost imparted by the FKS2 mutation. To uncover
mechanisms that abrogate echinocandin resistance, we turned to
Hsp90 and found that genetic or pharmacological compromise of
C. glabrata Hsp90 function reduced basal tolerance and resistance
of clinical isolates. Compromising calcineurin function pharma-
cologically or genetically phenocopied compromising Hsp90
function. Caspofungin induced FKS2 expression in a manner that
depended upon Hsp90 and calcineurin, providing a molecular
mechanism by which Hsp90 and calcineurin regulate echinocan-
din resistance. Furthermore, one of the clinical isolates in the series
is a petite mutant based on morphology and inability to respire;
although the petite phenotype was not intrinsically involved in
echinocandin resistance, it imparted resistance to the combination
of echinocandins and inhibitors of Hsp90 or calcineurin. In a
mouse model of candidemia, the petite mutant was rapidly cleared
and completely avirulent while infection with the HSP90-
repressible strain yielded a reduced fungal burden compared to
wild type. Thus, our results provide the first global view of
mutations that accompany the evolution of fungal drug resistance
in a human host, implicate the first compensatory mutation that
mitigates the cost of echinocandin resistance, and suggest a new
molecular mechanism regulating echinocandin resistance, with
broad therapeutic potential.
Results
The evolution of echinocandin resistance in C. glabrata in
a human host
While numerous echinocandin-resistant isolates have been
recovered from patients [34–37], in most cases, there has not
been adequate sampling over the course of drug treatment to
identify related fungal lineages with which to study the evolution of
drug resistance in the human host. The most detailed sampling
includes a clinical isolate pre-caspofungin treatment and two
isolates taken serially post-caspofungin treatment, however, the
mechanism by which resistance evolved was not investigated [50].
In contrast, series of clinical isolates recovered over time from
patients undergoing treatment with azoles have proven instru-
mental for dissecting mechanisms of azole resistance in C. albicans
[44,51–55]. The more detailed sampling and analysis of the
evolution of resistance to azoles likely reflect the fact that azoles
have been used clinically for a longer duration.
We report here on a series of C. glabrata isolates recovered over a
10-month period from a 45-year old female patient with Crohn’s
disease who suffered from recurrent C. glabrata candidemia and
underwent multiple rounds of caspofungin treatment before
ultimately succumbing to the infection. A case report on the
details of the patient history and therapeutic interventions is
provided in the Materials and Methods. Given that multiple blood
cultures were negative prior to stopping treatment at any interval
and that susceptibility testing was not routinely performed at the
time of treatment, caspofungin remained the main therapeutic
intervention for candidemia. The 7 blood culture isolates analyzed
are labeled alphabetically in the order in which they were
recovered, such that isolate A was recovered prior to caspofungin
treatment and isolate G was recovered 10 months after recurrent
infection and several rounds of caspofungin treatment. The isolates
were determined to be related based on molecular typing analysis
including pulsed-field gel electrophoresis (PFGE) - karyotype
analysis (Figure S1), as well as restriction enzyme PFGE using SfiI
(data not shown). Antifungal susceptibility of the 7 isolates in the
series was determined for caspofungin, as well as for numerous
azoles (fluconazole, ketoconazole, itraconazole, and voriconazole)
and for amphotericin B, which binds to ergosterol and disrupts
membrane integrity [20], using broth microdilution with RPMI
1640 and following the standard CLSI M27-A3 protocol [56]
(Table S1). The major trend observed was an increase in
caspofungin resistance over the course of treatment. There were
only minimal changes in susceptibility to the other antifungal
drugs tested, with the exception of an increase in resistance to
azoles that peaked at isolate F and returned to intermediate levels
at isolate G. Because the patient was not treated with azoles, the
changes in azole susceptibility may be due to mutations that arose
in the lineage due to genetic drift rather than selection, or may
reflect additional phenotypic consequences of mutations associated
with echinocandin resistance, mutations associated with adapta-
tion to the bloodstream, or mutations that were not directly
selected for but simply hitch-hiked along with mutations under
selection in this predominantly clonal system.
Whole genome sequencing reveals 9 non-synonymous
mutations between early clinical isolate A and late
clinical isolate G
The genomic spectrum of resistance mutations that emerge
during the evolution of a fungal pathogen in its human host can be
addressed for the first time using next-generation sequencing
technology and the series of C. glabrata clinical isolates we describe
here. As a haploid, genome analysis of C. glabrata is simplified
Evolution of Echinocandin Resistance
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and gene conversion can amplify the number of polymorphisms
observed between early and late isolates (changes from heterozy-
gous to homozygous states are also classified as nucleotide changes)
and thereby hinder functional analysis of mutations conferring
resistance. Further, C. glabrata shares a recent common ancestor
with the model yeast S. cerevisiae with a large number of orthologs
between the two species, facilitating bioinformatic analysis [21,22].
Given the clinical importance of echinocandin resistance, and that
to date resistance has only been attributed to mutations in the
echinocandin target [33,36–39], with evidence that additional
resistance determinants and modulators may remain to be
discovered [20,37,40], we sought to identify the mutations that
accompany the evolution of echinocandin resistance in the human
host on a genome-wide scale.
We performed whole genome sequencing of the C. glabrata
isolate recovered prior to caspofungin treatment (isolate A) and the
last isolate recovered after multiple rounds of treatment (isolate G)
using the Illumina Genome Analyzer II platform. We obtained 5.1
and 3.8 million 76 base pair single-end reads for isolate A and
isolate G, respectively, resulting in 22 to 306 genome coverage.
Reads were aligned against the reference genome sequence of
CBS138 [57]. Single nucleotide variants were identified using a
machine learning approach. A total of 45,797 single nucleotide
variants were identified between late clinical isolate G and
CBS138. Of these single nucleotide variants, 39,146 had sufficient
sequencing depth in isolate A to be reliably assigned. Overall, 26
single nucleotide variants were uncovered between isolate A and
G, with only 17 of these within open reading frames and only 9
resulting in non-synonymous changes (Table 1). Although the 9
mutations that were not within open reading frames (Table 2)
could include mutations that affect regulation of genes important
for drug resistance, we focused our analysis on mutations within
open reading frames given that silent mutations can more readily
be distinguished from those with functional consequences in
coding sequences and given their potential impact on gene product
function. All 9 non-synonymous changes were verified and then
mapped across isolates B to F using Sanger sequencing to
determine when each mutation arose in the series (Figure 1).
Genes are named based on homology to S. cerevisiae genes [57].
Mutations in the MOH1, GPH1, CDC6, and TCB1/2 genes
accompanied the first modest increase in resistance in the series at
isolate C (Figure 1). The function of MOH1 in S. cerevisiae is largely
unknown except that it is required for survival in stationary phase
[58,59], and it was found to genetically interact with Hsp90 in a
genome-wide chemical-genetic screen [60]. Expression of C.
albicans MOH1 is induced by alpha pheromone in filament-
inducing Spider medium, by weak acid stress via Mnl1, and in
biofilm conditions [61–63]. GPH1 encodes a glycogen phosphor-
ylase regulated by the high osmolarity glycerol (HOG) mitogen-
activated protein (MAP) kinase pathway in S. cerevisiae [64,65], and
is induced upon fluconazole treatment in C. albicans [66]. The
CDC6 gene product is involved in DNA replication initiation by
forming and maintaining the pre-replicative complex and serving
as a loading factor for the Mcm2–7 proteins onto chromatin
[67,68]. TCB1 and TCB2 encode proteins containing both calcium
and lipid binding domains and appear to be involved in
membrane trafficking in S. cerevisiae [69,70]. None of these genes
or proteins have been previously implicated in echinocandin
resistance.
Additional mutations emerged accompanying the subsequent
major increase in echinocandin resistance, and in the last isolate of
the series. Mutations in FKS2, DOT6, MRPL11, and SUI2
accompanied the largest increase in echinocandin resistance at
isolate D (Figure 1). Of these genes, only FKS2 has been implicated
in echinocandin resistance. FKS2 encodes the catalytic subunit of
Table 1. Whole genome sequencing reveals 17 single nucleotide variants (SNVs) within open reading frames between early
clinical isolate A and late clinical isolate G.
Gene S. cerevisiae Homolog A Codon G Codon A Amino Acid G Amino Acid Codon Position
CAGL0F04631g MOH1 TAC CAC Y H 5
CAGL0F04895g GPH1 CAC TAC H Y 409
CAGL0K00605g CDC6 AAA GAA K E 171
CAGL0J08591g TCB1/2 GCA GTA A V 1161
CAGL0K04037g FKS2 TCT CCT S P 663
CAGL0A04257g DOT6 AAA TAA K Stop 347
CAGL0J09724g MRPL11 TAC CAC Y H 161
CAGL0B03795g SUI2 ATC ATG I M 121
CAGL0L06182g CDC55 CCA TCA P S 155
CAGL0A00517g PMC1 GGT GGC G G 241
CAGL0B04279g RKM3 GGT GGC G G 49
CAGL0C02211g UTR2 TTC TTT F F 11
CAGL0D03344g UBR2 TCG TCA S S 1681
CAGL0I02288g CDC23 TGC TGT C C 42
CAGL0J07040g GDE1 GTA GTC V V 495
CAGL0M04653g PEP3 TTA TTG L L 633
CAGL0M13541g TDA1 ATC ATT I I 83
Whole genome sequencing was performed on clinical isolates A and G using the Illumina GAII platform. All high-confidence SNVs located within predicted open reading
frames identified between the early clinical isolate A and late clinical isolate G are listed. Genome coverage of 22 to 306was obtained, with a total of 45,797 SNVs
identified between isolate A and the reference CSB138 strain.
doi:10.1371/journal.ppat.1002718.t001
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Fks2 S663P mutation identified is in mutational hot spot 1 and has
been found in other echinocandin-resistant C. glabrata clinical
isolates [36,37,71]. Dot6 is a subunit of the RPD3L histone
deacetylase complex in S. cerevisiae and is involved in both
pseudohyphal morphogenesis as well as silencing at telomeres
[72–74]. Mrpl11 is a mitochondrial protein and part of the large
ribosomal subunit [75,76]. SUI2 plays a role in translation
initiation and encodes the alpha subunit of the translation
initiation factor eIF2 in S. cerevisiae [77]. Finally, a non-
synonymous mutation occurred in CDC55 in the latest clinical
isolate G, despite no further increase in echinocandin resistance
(Figure 1). CDC55 encodes the regulatory B subunit of protein
phosphatase 2A and has a number of functions, including roles in
spindle assembly during meiosis, mitotic exit, pseudohyphal
morphogenesis, and chromosome disjunction [78–81].
Thus, in addition to a mutation in the known echinocandin
target, whole genome sequencing revealed the acquisition of 8
additional non-synonymous mutations in 8 genes not previously
implicated in echinocandin resistance or adaptation to host
conditions during the evolution of echinocandin resistance in a
human host. The genome sequence analysis further confirms
clonality of the lineage given the very limited number of single
nucleotide variants genome-wide compared to large number
Table 2. Whole genome sequencing reveals 9 single nucleotide variants (SNVs) that lie outside predicted open reading frames
between early clinical isolate A and late clinical isolate G.
(Chromosome) Coordinate Substitution Most Proximal Gene(s) Mutation Position S. cerevisiae Homolog
(Cagl0L) 63245 C to G CAGL0L00539g 803 bp downstream ADD37
(Cagl0M) 1164711 A to T CAGL0M11704g (AHP1) 608 bp upstream AHP1
(Cagl0J) 162944 A to G 1. CAGL0J01774g 1864 bp downstream N/A
2. CAGL0J01727g 2163 bp upstream N/A
(Cagl0L) 1294054 C to A 1. CAGL0L12034g 243 bp upstream ECM32
2. CAGL0L12012g 480 bp upstream TMT1
(Cagl0J) 46946 T to C 1. CAGL0J00539g (SLT2) 149 bp upstream SLT2
2. CAGL0J00517g 572 bp downstream RRM3
(Cagl0F) 705090 A to G CAGL0F07249g 486 bp upstream TAF6
(Cagl0D) 91734 T to C CAGL0D00704g 316 bp downstream YET3
(Cagl0C) 90199 T to C CAGL0C00847g (EPA8) 1696 bp downstream FLO10
(Cagl0K) 573053 G to T CAGL0K05841g (HAP1) 91 bp upstream HAP1
All high-confidence SNVs that were found outside of predicted open reading frames between early clinical isolate A and late clinical isolate G are listed. Their genome
coordinates, the base pair substitution, the most proximal gene(s), the position of the mutation relative to that gene, as well as the gene homolog in S. cerevisiae are
listed.
doi:10.1371/journal.ppat.1002718.t002
Figure 1. Non-synonymous mutations that accumulate in C. glabrata during the evolution of echinocandin resistance in a human
host. C. glabrata clinical isolates display a step-wise increase in caspofungin resistance in a Minimum Inhibitory Concentration (MIC) assay. Isolates
are arranged in the same order as they were recovered from the patient, where isolate A was recovered pre-treatment and isolate G was recovered
after multiple rounds of caspofungin treatment. Assays were performed in RPMI medium with 2% glucose at 30uC for 72 hours. Optical densities were
averaged for duplicate measurements and normalized relative to caspofungin-free controls (see color bar). The nine non-synonymous mutations
identified in isolate G compared to isolate A using whole genome sequencing (marked in red) were mapped across isolates B to F using Sanger
sequencing. Mutations in MOH1, GPH1, CDC6, and TCB1/2 occur between isolates B and C, which correspond to a small increase in echinocandin
resistance, outlined in blue boxes. Mutations in DOT6, MRPL11, FKS2, and SUI2 correspond to a sharp increase in echinocandin resistance, outlined in
black boxes.
doi:10.1371/journal.ppat.1002718.g001
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genome CBS138. Further, that each of the mutations identified
persisted throughout the lineage once it emerged suggests that
there may have been strong selective sweeps in the population
such that polymorphisms rapidly reached near fixation.
The FKS2 T1987C (S663P) mutation confers echinocandin
resistance and imparts a fitness deficit in a C. glabrata
laboratory strain
To determine which of the mutations identified by whole
genome sequencing contributes to echinocandin resistance we first
turned to the most likely candidate resistance gene, FKS2. The
FKS2 mutation that emerged in isolate D and was maintained
throughout the rest of the series (T1987C) results in substitution of
a serine to proline at amino acid 663 in the target of the
echinocandins. This FKS2 T1987C (S663P) mutation has been
previously associated with high levels of caspofungin resistance in
C. glabrata clinical isolates [36,37]. In vitro biochemical studies
established that this mutant Fks2 enzyme displays reduced
sensitivity to inhibition by echinocandins, as indicated by a higher
kinetic inhibition parameter, as well as decreased catalytic
capacity, and reduced enzyme velocity, compared to the wild-
type enzyme; notably the binding affinity of the mutant enzyme
for echinocandins remains unchanged [36]. While there is an
association of FKS mutations with resistance, and biochemical data
support the resistance mechanism, it has only been conclusively
demonstrated that such mutations are sufficient to confer
echinocandin resistance in S. cerevisiae [82,83]. To test whether
Fks2 S663P is sufficient to confer echinocandin resistance, we
introduced the T1987C mutation into the sensitive laboratory
strain BG2 using a strategy involving single-stranded DNA
containing the mutation and a silent marker, followed by selection
of transformants on medium containing caspofungin. No echino-
candin-resistant colonies were obtained following control trans-
formations with single-stranded DNA containing the equivalent
wild-type sequence or with a water control, while many resistant
colonies were obtained with the sequence containing the T1987C
mutation. We assessed resistance of four sequence-verified
transformants that harboured both the T1987C and silent
mutation via minimum inhibitory concentration (MIC) assays.
The transformants displayed resistance similar to clinical isolate G
(Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin
resistance in a susceptible laboratory strain of C. glabrata.
Given that specific Fks amino acid substitutions that decrease
sensitivity of the 1,3-b-D-glucan synthase enzyme to echinocan-
dins also reduce the enzyme catalytic capacity, the Fks2 S663P
mutation may confer a fitness cost in terms of reduced growth or
viability in the absence of the drug [36,39]. To determine if the
FKS2 mutations compromises fitness, we monitored growth
kinetics of the lab strain BG2 and the progeny harbouring the
Fks2 S663P substitution. In clinically relevant conditions, RPMI at
37uC, we found that strains harbouring the Fks2 S663P
substitution displayed significantly reduced fitness relative to the
parental wild-type laboratory strain BG2 (P,0.01, area under the
curve followed by ANOVA, Bonferroni’s Multiple Comparison
Test, Figure 2B, left panel). Furthermore, we observed a significant
reduction in fitness between isolate A and isolate D (P,0.001),
which is rescued to some extent in isolate G (P,0.01, Figure 2B,
right panel). Thus, the FKS2 mutation that emerged in clinical
isolate D is sufficient to confer a high level of caspofungin
resistance equivalent to that observed in the late isolate G,
however, it is also associated with a cost in terms of reduced fitness
in the absence of the drug.
The fitness cost associated with the FKS2 T1987C (S663P)
mutation is mitigated by increased dosage of CDC55
Compensatory mutations that mitigate the cost of drug
resistance have been well established in bacterial systems [84–
87], but remain enigmatic in fungi. Given the fitness cost
associated with echinocandin resistance due to mutation in the
drug target observed in this study, and in others [88], one would
anticipate selection to favour the emergence of compensatory
mutations that mitigate the fitness cost of the resistance mutation.
The series of C. glabrata isolates studied here provide the ideal
opportunity to identify compensatory mutations given that a single
non-synonymous mutation occurs between isolate D and G,
CDC55 C463T (P155S), associated with an increase in fitness
(Figure 1). The CDC55 C463T allele from late clinical isolate G
was cloned into a plasmid under the control of its native promoter,
as was the CDC55 allele from the early clinical isolate A, and
introduced into the BG2 laboratory strain harbouring the FKS2
T1987C mutation. Monitoring growth kinetics of two independent
transformants harbouring each of the CDC55 plasmids relative to
two transformants with the empty vector control demonstrates that
the additional copy of CDC55 ameliorates fitness (P,0.01,
ANOVA, Bonferroni Multiple Comparison Test, Figure 3). This
suggests that perhaps the CDC55 C463T mutation might be a gain-
of-function mutation, such that increased fitness could be achieved
either by mutation causing increased Cdc55 activity or by
increased dosage of CDC55. These results identify the premier
genetic alteration that mitigates the fitness cost of echinocandin
resistance.
A mutation in CDC6 confers a small increase in
echinocandin resistance
Despite the fact that the FKS2 T1987C mutation was sufficient
to impart the full level of caspofungin resistance of isolate G on an
otherwise susceptible laboratory strain (Figure 2A), there is
evidence for additional mutations affecting resistance in the
evolved lineage. The initial small increase in echinocandin
resistance observed at isolate C (Figure 1) occurred prior to the
FKS2 mutation and thus other mutations identified at this early
transition may be responsible for this increase in resistance.
Notably, isolate C showed a fitness defect in the absence of drug
(Figure 2B), suggesting that the mutations imparting this small
increase in resistance are also costly. Additional mutations that
accumulated could mitigate the fitness cost of resistance mutations.
To prioritize mutations for functional analysis, we addressed the
prevalence of mutations in any of the 8 genes found to harbour
mutations in our whole genome sequence analysis in addition to
FKS2 in other C. glabrata echinocandin-resistant mutants. To do so,
we obtained 10 additional unrelated C. glabrata clinical isolates
harbouring the Fks2 S663P mutation [71], and sequenced across
the 8 genomic regions that were mutated in clinical isolate G via
Sanger sequencing. We discovered non-synonymous changes in
MOH1 in two out of the 10 clinical isolates sequenced and non-
synonymous changes in CDC6 in 7 out of 10 of the clinical isolates
(Figure 4). Given the prevalence of polymorphisms in CDC6 and
MOH1 among these echinocandin-resistant clinical isolates, we
prioritized these genes for functional analysis. We cloned plasmids
with the gene sequences found in isolate A or in isolate G, and
expressed these in a susceptible laboratory strain. While the
MOH1-T13C(Y5H) allele did not confer any increase in echino-
candin resistance (data not shown), the CDC6-A511G(K171E) allele
did confer a small increase in resistance (Figure 5). Thus, we
establish a novel mutation in CDC6 that contributes to reduced
echinocandin susceptibility in C. glabrata clinical isolates.
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PLoS Pathogens | www.plospathogens.org 6 May 2012 | Volume 8 | Issue 5 | e1002718Figure 2. The FKS2 T1987C (Fks2 S663P) mutation is sufficient for echinocandin resistance in a C. glabrata laboratory strain and
imparts a fitness cost in the absence of the drug. (A) The FKS2 T1987C (Fks2 S663P) mutation uncovered in caspofungin-resistant clinical isolate
G was introduced into a sensitive laboratory C. glabrata strain BG2 via single-stranded DNA containing a silent marker. Resistance profiles of three
independent sequence-verified transformants were tested via MIC. MIC assays were performed in Figure 1 and plotted graphically as caspofungin
concentration (mg/ml) versus optical density at 600 nm. (B) Growth kinetics of the BG2 laboratory strain of C. glabrata and three independent
transformants harbouring a mutant FKS2 T1987C allele (left panel) and of the C. glabrata clinical isolate series (right panel). Growth curves were
performed in RPMI medium at 37uC with orbital shaking, with measurements taken every 15 minutes for 48 hours.
doi:10.1371/journal.ppat.1002718.g002
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PLoS Pathogens | www.plospathogens.org 7 May 2012 | Volume 8 | Issue 5 | e1002718Hsp90 plays a critical role in echinocandin resistance of C.
glabrata clinical isolates
Given the importance of echinocandins in the therapeutic front
line against C. glabrata infections and the acute problem imposed by
the evolution of echinocandin resistance, there is a pressing need to
discoverstrategiestoabrogatedrug resistance.Wefocused onHsp90
due to its critical role in enabling basal tolerance and acquired
antifungal drug resistance in pathogenic fungi such as C. albicans and
the most lethal mould Aspergillus fumigatus [41,44,45,47]. In the
context of the echinocandins, C. albicans Hsp90 orchestrates crucial
cellularresponsestosurvive echinocandin exposurebystabilizing the
catalytic subunit of the protein phosphatase calcineurin, while in S.
cerevisiae Hsp90 and calcineurin do not modulate echinocandin
susceptibility under any of the standard conditions tested [41]. To
date, no studies have examined the consequences of pharmacolog-
ical or genetic compromise of Hsp90 function on cellular responses
toechinocandinsinC.glabrata, and thus whether this pathogen shows
resistance circuitry more akin to the pathogen C. albicans or its closer
relative S. cerevisiae remains unknown.
We first implemented a pharmacological approach to determine
if inhibition of Hsp90 modulates echinocandin resistance of C.
glabrata. We monitored growth across a gradient of the widely used
echinocandin caspofungin relative to a drug-free growth control in
the presence or absence of the two structurally unrelated Hsp90
inhibitors, geldanamycin and radicicol, that bind to the adenosine
triphosphate (ATP) binding pocket of Hsp90 and thereby
compromise ATP-dependent chaperone function [89,90]. In the
absence of geldanamycin, there was a small increase in
caspofungin resistance between isolate B and isolate C and a
large increase in resistance between isolate C and isolate D
(Figures 1 and 6A). Pharmacological inhibition of Hsp90 with
geldanamycin or radicicol decreased tolerance of the early clinical
isolates A, B, and C, and reduced resistance of the late clinical
isolates D, E, and G (Figure 6A). Synergy between caspofungin
and geldanamycin was also observed in RPMI, a medium used for
clinical susceptibility testing (Figure S2). Notably, isolate F was
refractory to the synergy between caspofungin and Hsp90
inhibitors, as discussed in more detail below.
Next, we validated our pharmacological findings genetically.
We engineered a strain of C. glabrata in which the only HSP90
allele was expressed under the control of the MET3 promoter,
which is repressed in the presence of methionine and/or cysteine.
We monitored the impact of a gradient of methionine concentra-
tions on growth across a gradient of caspofungin concentrations
for both isolate G and its derivative in which HSP90 expression is
driven by the MET3 promoter. Methionine had no impact on
caspofungin resistance of isolate G (Figure 6B). In contrast,
methionine reduced echinocandin resistance of the MET3p-HSP90
derivative of isolate G in a dose-dependent manner, providing
genetic validation of the importance of Hsp90 for echinocandin
resistance (Figure 6B). The highest concentrations of methionine
tested ($1 mg/ml) blocked growth of the MET3p-HSP90 strain,
consistent with Hsp90’s essentiality in all eukaryotes tested. Thus,
targeting Hsp90 provides the first and much-needed strategy to
abrogate echinocandin resistance of C. glabrata.
Compromising calcineurin function abrogates
echinocandin resistance of C. glabrata clinical isolates
Hsp90 enables resistance to both the azoles and echinocandins,
in large part via the protein phosphatase calcineurin in C. albicans
[3,41,44,47]. Hsp90 stabilizes the catalytic subunit of calcineurin
in both S. cerevisiae and C. albicans [41,91], thereby enabling
calcineurin-dependent responses to drug-induced cellular stress
[3,92]. While calcineurin has been implicated in basal tolerance to
echinocandins in C. glabrata [49], whether calcineurin affects bona
fide resistance remains unknown.
We used both pharmacological and genetic approaches to
determine if calcineurin is a key mediator of Hsp90-dependent
Figure 3. Increased dosage of CDC55 compensates for the fitness cost associated with the echinocandin resistance mutation FKS2
T1987C (Fks2 S663P) in C. glabrata. Either the wild-type (WT) CDC55 allele of clinical isolate A or the CDC55 C463T (Cdc55 P155S) allele of the late
resistant clinical isolate G was expressed on a plasmid under the control of its native promoter in a C. glabrata laboratory strain harbouring the
echinocandin resistance mutation FKS2 T1987C (Fks2 S663P). Growth kinetics of two independent transformants harbouring the FKS2 T1987C mutant
allele and either the CDC55 C463T or CDC55 WT ectopically expressed allele, as well as a control strain harbouring an empty vector, were assessed.
Growth curves were performed in RPMI medium at 37uC with orbital shaking, with measurements taken every 15 minutes for 48 hours.
doi:10.1371/journal.ppat.1002718.g003
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PLoS Pathogens | www.plospathogens.org 8 May 2012 | Volume 8 | Issue 5 | e1002718Figure 4. Polymorphisms in MOH1 and CDC6 are prevalent in C. glabrata clinical isolates with FKS2-mediated echinocandin
resistance. Genomic regions harbouring the 9 non-synonymous mutations uncovered in isolate G relative to isolate A were sequenced by Sanger
sequencing in 10 unrelated C. glabrata echinocandin-resistant clinical isolates containing the resistance mutation FKS2 T1987C/Fks2 S663P.
Synonymous mutations are in black font; non-synonymous mutations are in red with amino acid mutations listed in parentheses. Sequences were
compared to both the reference CBS138 sequence as well as a control sample sequenced from the laboratory isolate BG2 (CgLC1272).
doi:10.1371/journal.ppat.1002718.g004
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PLoS Pathogens | www.plospathogens.org 9 May 2012 | Volume 8 | Issue 5 | e1002718echinocandin resistance in C. glabrata. First, we took a pharma-
cological approach and assessed growth across a gradient of
caspofungin concentrations in the presence or absence of two
structurally unrelated calcineurin inhibitors, cyclosporin A and
FK506. Cyclosporin A and FK506 inhibit calcineurin function in
different ways. Cyclosporin A binds to cyclophilin A, a peptidyl-
prolyl cis-trans isomerase, and it is this drug-protein complex that
inhibits calcineurin function [93]. FK506 binds a structurally
unrelated peptidyl-prolyl cis-trans isomerase, FKBP12, and this
distinct drug-protein complex also inhibits calcineurin function
[93]. We used concentrations of each calcineurin inhibitor that
abolished echinocandin resistance in C. albicans but did not inhibit
growth on their own [41]. We found that inhibition of calcineurin
with cyclosporin A or FK506 reduced caspofungin resistance of
the late resistant C. glabrata clinical isolate G (Figure 7A). Next, we
validated our pharmacological findings genetically by deletion of
the regulatory subunit of calcineurin, encoded by CNB1, which is
required for calcineurin function. Loss of calcineurin function
reduced resistance of clinical isolate G in three independent
mutants (Figure 7A). Thus, calcineurin is a key mediator of Hsp90-
dependent echinocandin resistance in C. glabrata.
Since the clinical isolate G harbours multiple mutations relative
to its echinocandin-susceptible counterpart, we next specifically
assessed the dependence of Fks2-mediated echinocandin resistance
on Hsp90 and calcineurin. Pharmacological inhibition of Hsp90
with geldanamycin, or calcineurin with cyclosporin A reduced
echinocandin resistance of the laboratory strain harbouring the
FKS2 T1987C allele (Figure 7B), confirming that both Hsp90 and
calcineurin are required for echinocandin resistance acquired by
mutation of the drug target and providing the first circuitry that
governs echinocandin resistance in this pathogen.
Caspofungin induces FKS2 expression in a calcineurin-
and Hsp90-dependent manner in C. glabrata
The specific mechanism by which calcineurin governs echino-
candin resistance remains unknown in any system. In S. cerevisiae,
FKS2 expression is induced during high temperature growth via
calcineurin, and deletion of both FKS1 and FKS2 is synthetically
lethal [94–97]. Based on these findings, we propose a model in
which calcineurin regulates echinocandin resistance in C. glabrata
by controlling expression of the resistance determinant FKS2.
Given the functional dependence of calcineurin on Hsp90 in other
systems [41,44,91], one might expect Hsp90 to also influence
expression of FKS2. According to our model, inhibition of
calcineurin or Hsp90 would compromise expression of the
echinocandin-resistant 1,3-b-D-glucan synthase and reduce resis-
tance. Compromising calcineurin or Hsp90 function would also
reduce basal tolerance of susceptible strains by reducing FKS2
expression, thereby decreasing the cellular pool of 1,3-b-D-glucan
synthase and enhancing susceptibility to a given concentration of
echinocandin.
To test this model, we used quantitative RT-PCR to measure
transcript levels of FKS2, encoding the catalytic subunit of 1,3-b-
D-glucan synthase, in the echinocandin-resistant clinical isolate G
and derivatives in which we deleted the regulatory subunit of
calcineurin required for its function, encoded by CNB1,o ri n
which we reduced HSP90 levels. Transcript levels of CNB1,
HSP90, and FKS2 were monitored after growth in rich medium for
one hour with or without caspofungin treatment. We found that
caspofungin induced expression of both CNB1 (P,0.001, AN-
OVA, Bonferroni’s Multiple Comparison Test, Figure 8A) and
FKS2 (P,0.001, Figure 8A). Importantly, deletion of CNB1
blocked caspofungin-induced upregulation of FKS2 (P,0.001,
Figure 8A). To reduce HSP90 levels in the MET3p-HSP90 strain,
we included methionine in the medium for both this strain and the
wild-type control at a concentration that had minimal impact on
growth (0.25 mg/ml). HSP90 levels were reduced in the MET3p-
HSP90 strain relative the wild-type control (P,0.001, Figure 8B).
Caspofungin-dependent induction of FKS2 was significantly
reduced in the MET3p-HSP90 strain (P,0.001, Figure 8B),
suggesting that Hsp90 enables FKS2 expression. Taken together,
these results establish that FKS2 is induced upon echinocandin
exposure, and that full induction of the resistance determinant
FKS2 is dependent on both calcineurin and Hsp90. This provides a
novel mechanism by which calcineurin and Hsp90 regulate
echinocandin resistance in pathogenic fungi.
Figure 5. The CDC6 A511G (Cdc6 K171E) mutation uncovered in clinical isolate C imparts a small increase in echinocandin
resistance in C. glabrata. The mutant allele of CDC6 that was identified in clinical isolate C and accompanied a small increase in echinocandin
resistance, or a wild-type allele of CDC6 cloned from the early sensitive isolate A, was expressed on a plasmid under the control of its native promoter
and introduced as the only copy of CDC6 in a laboratory strain of C. glabrata. Caspofungin resistance of two independent transformants of strains
harbouring the mutant or wild-type CDC6 allele was assessed using an MIC assay. Assays were performed in synthetic defined medium at 30uC for
72 hours. Data was analyzed as in Figure 1.
doi:10.1371/journal.ppat.1002718.g005
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PLoS Pathogens | www.plospathogens.org 10 May 2012 | Volume 8 | Issue 5 | e1002718Figure 6. Hsp90 plays a critical role in echinocandin resistance of C. glabrata clinical isolates. (A) Pharmacological inhibition of Hsp90 with
geldanamycin or radicicol reduces caspofungin resistance of C. glabrata clinical isolates in an MIC assay. Isolates are arranged in the same order as
they were recovered from a patient who was on caspofungin treatment, where isolate A was recovered pre-treatment and isolate G was recovered
after multiple rounds of caspofungin treatment. Assays were done in synthetic defined medium at 30uC for 72 hours. Data was analyzed as in Figure 1.
(B) Genetic depletion of Hsp90 confers hypersusceptibility to caspofungin. Growth of the late, echinocandin-resistant clinical isolate G and its
derivative in which HSP90 expression is driven by the methionine-repressible MET3 promoter was assessed in a checkerboard format with a gradient
of caspofungin and a gradient of methionione. Methionine had no impact on caspofungin resistance of isolate G, but increased the susceptibility of
the MET3p-HSP90 strain in a concentration-dependent manner.
doi:10.1371/journal.ppat.1002718.g006
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PLoS Pathogens | www.plospathogens.org 11 May 2012 | Volume 8 | Issue 5 | e1002718Figure 7. Calcineurin is a key-mediator of Hsp90-dependent echinocandin resistance of C. glabrata. (A) Genetic or pharmacological
compromise of calcineurin function reduces echinocandin resistance of the clinical isolates. Deletion of the regulatory subunit of calcineurin, CNB1,
required for calcineurin function reduces caspofungin resistance in resistant clinical isolates. Pharmacological inhibition of calcineurin with either
cyclosporin A or FK506 also reduces caspofungin resistance. The assay was performed and analyzed as in Figure 1. (B) Resistance of the laboratory
strain BG2 harbouring the T1987C FKS2 mutant allele is reduced upon inhibition of calcineurin with cyclosporin A or inhibition of Hsp90 with
geldanamycin. Assays were performed as in part (A) and data was analyzed as in Figure 1.
doi:10.1371/journal.ppat.1002718.g007
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PLoS Pathogens | www.plospathogens.org 12 May 2012 | Volume 8 | Issue 5 | e1002718Figure 8. Caspofungin induces FKS2 expression in a calcineurin- and Hsp90-dependent manner in C. glabrata. (A) Caspofungin induces
expression of CNB1, which encodes the regulatory subunit of calcineurin, and FKS2, which encodes 1,3-b-D-glucan synthases, in the late clinical
isolate G but not in its derivative lacking CNB1. Transcript levels of the regulatory subunit CNB1 (left panel) and FKS2 (right panel) were measured by
quantitative RT-PCR after growth in rich medium at 30uC for one hour with or without caspofungin (CF) at 120 ng/ml, as indicated. Transcript levels
are normalized relative to ACT1. Expression is relative to the untreated sample, which was set to 1. Data are means 6 standard deviation for triplicate
samples and representative of two independent biological replicate experiments. Three asterisks indicate P,0.001 (ANOVA, Bonferroni’s Multiple
Comparison Test). (B) Caspofungin induces expression of resistance determinant FKS2 in the late clinical isolate G, but induction is reduced in its
MET3p-HSP90 derivative (P,0.001). Transcript levels of HSP90 and FKS2 were measured by quantitative RT-PCR after growth in conditions listed in (A),
and in the presence of methionine at a concentration that had minimal impact on growth (0.25 mg/ml). Data are analyzed as in (A).
doi:10.1371/journal.ppat.1002718.g008
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echinocandins, but are refractory to the synergy between
caspofungin and inhibitors of Hsp90 or calcineurin
Respiratorydeficientmutantswithlossofmitochondrialfunction,
referred to as petite mutants, are associated with azole resistance in
S. cerevisiae, C. albicans,a n dC. glabrata [98–102]. To date, there have
been no reports of the petite phenotype contributing to echino-
candin resistance, although C. glabrata is able to produce petite
mutants at high frequency in vitro as well as in vivo [98,101,103].
Isolate F in our C. glabrata series was isolated from the patient at the
same time point as isolate E, however, it was morphologically
distinct and thus archived separately (Text S1). When cultured on
rich medium containing dextrose as the carbon source, this isolate
had a reduced growth rate relative to the other isolates and
produced smaller more transparent colonies (Figure 9A), despite
possessing the same karyotype (Figure S1) and complement of
polymorphisms in the nuclear genome as isolate E (Figure 1). When
cultured on rich medium containing glycerol as the carbon source,
which is non-fermentable, isolate F was unable to grow (Figure 9A).
These results suggests that isolate F is a petite mutant as it behaves
morphologically as a petite and is unable to respire based on failure
to grow on glycerol. Notably, isolate F had a distinct echinocandin
resistance phenotype from the other resistant isolates in the series in
that its resistance was maintained even in the presence of the Hsp90
inhibitors geldanamycin or radicicol (Figure 6), or the calcineurin
inhibitor cyclosporin A (Figure 9).
To determine if the petite phenotype is intrinsically involved in
echinocandin resistance of C. glabrata clinical isolates, petite mutants
were generated from clinical isolate A and their resistance profiles
were tested via MIC assays (Figure 9B). If the petite phenotype is
sufficient to impart echinocandin resistance, then petite mutants
generated from isolate A should acquire resistance, however, they
do not (Figure 9B). This suggests that the petite phenotype is not
intrinsically involved in C. glabrata echinocandin resistance.
To determine if petite mutants of C. glabrata are intrinsically
refractory to the synergy between echinocandins and inhibitors of
Hsp90 or calcineurin, petite mutants were generated from late
clinical isolate G and their resistance profiles were tested via MIC
assays (Figure 9C). The petite mutants generated from isolate G
are indeed resistant to the combination of caspofungin and
geldanamycin or cyclosporin A, suggesting that they either no
longer require calcineurin or Hsp90 for FKS2-mediated resistance,
or that they are simply resistant to geldanamycin and cyclosporin
A. Notably, petite mutants are known to up-regulate multidrug
efflux transporters [98], which may confer resistance to these
pharmacological inhibitors by their increased efflux from the cell.
To distinguish between these two possibilities, petite mutants were
generated from the isolate G derivative in which calcineurin
function was genetically compromised due to deletion of CNB1.I f
petite mutants no longer require calcineurin for echinocandin
resistance, then deletion of CNB1 should have no impact on
resistance, however, this was not the case (Figure 9D). Petite
mutants generated from isolate G cnb1D mutants were no longer
resistant to caspofungin, suggesting that petite mutants are able to
bypass the effects of cyclosporin A, and likely geldanamycin,
potentially due to up-regulation of efflux pumps.
Fungal burden of the C. glabrata clinical isolate series
and MET3p-HSP90 strain in a murine model of
disseminated infection
We next turned to a murine model of disseminated candidemia
to evaluate fitness of the series of clinical isolates and the impact of
reduction of Hsp90 levels in vivo. Mice were infected by tail vein
injection, and fungal burden in the kidney and spleen was assessed
7 days post infection. Infection with the initial clinical isolate A led
to kidney fungal burden greater than that observed with the
reference strain CBS138 (P,0.001, Kruskal-Wallis Test, Dunn’s
Multiple Comparison, Figure 10A). There was a trend towards
reduced fitness, as measured by kidney fungal burden, associated
with the early acquisition of echinocandin resistance (Figure 10A),
consistent with the trend observed in vitro (Figure 2B). Aside from
the petite mutant, isolate C showed the greatest reduction in fitness
of all the clinical isolates in the series relative to isolate A (P,0.05,
Figure 10A). This fitness cost was mitigated with further evolution
as shown by an increase in kidney fungal burden of isolate G
compared to isolate C (P,0.01, Figure 10A). Kidneys recovered
from mice infected with the petite mutant (isolate F) were
completely sterile (Figure 10A), consistent with the fitness deficit
observed in vitro (Figure 2B) and findings of reduced virulence of
some C. glabrata petite mutants [102,104]. Methionine levels in the
mouse are sufficient to repress gene expression from the MET3
promoter in C. albicans leading to avirulence of conditional mutants
[105], allowing us to test fungal burden of mice infected with the
MET3p-HSP90 strain. One of the two MET3p-HSP90 derivatives
of isolate G showed reduced kidney fungal burden relative to
isolate G (P,0.05, Figure 10A), consistent with the importance of
Hsp90 for growth in vitro and in vivo in a C. albicans murine model of
systemic infection [106]. The second MET3p-HSP90 derivative
also showed a trend towards reduced kidney fungal burden relative
to isolate G (Figure 10A). There were no significant differences
observed among any of the isolates tested in the spleen with the
exception of isolate F, for which the recovered spleens were sterile
(Figure 10B), suggesting that most of the mutations that
accumulated in the lineage have negligible impact on fitness in
this environment, and that methionine levels are likely not
sufficient to achieve substantial reduction of Hsp90 levels or that
Hsp90 has a less important role for fungal proliferation in the
spleen compared to the kidney. Thus, analysis of kidney fungal
burden in a mouse model of disseminated infection reveals a trend
towards reduced fitness accompanying early stages of echinocan-
din resistance that is ameliorated with further evolution, avirulence
associated with a petite mutant, and the importance of Hsp90 for
fitness in the host.
Discussion
Our results provide the first global view of mutations that
accompany the evolution of fungal drug resistance in a human
host, implicate the premier compensatory mutation that amelio-
rates the fitness cost of echinocandin resistance, and suggest a new
molecular mechanism regulating echinocandin resistance, with
broad therapeutic potential. We report on C. glabrata bloodstream
isolates that evolved increased resistance to the echinocandin
caspofungin over a 10-month period during which the patient
underwent multiple rounds of caspofungin treatment for recurrent
candidemia (Figure S1 and Table S1). This case demonstrates that
echinocandin resistance can evolve during treatment, and that an
undetected nidus of infection may contribute to fungal persistence
and drug resistance despite apparent adequate therapy and
documentation of negative blood cultures after treatment,
emphasizing the importance of routine antifungal susceptibility
testing. Whole genome sequencing of the susceptible isolate
recovered prior to drug treatment and the last resistant isolate
revealed that 9 non-synonymous mutations accumulated during
evolution in the human host (Table 1 and Figure 1). A mutation in
FKS2, encoding the drug target, accompanied the largest increase
in echinocandin resistance in the lineage; this mutation was
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PLoS Pathogens | www.plospathogens.org 14 May 2012 | Volume 8 | Issue 5 | e1002718Figure 9. Clinical isolate F is a petite mutant and is refractory to the synergy between caspofungin and Hsp90 or calcineurin
inhibitors. (A) Clinical isolate F is a petite mutant. Each clinical isolate from the C. glabrata echinocandin-resistant series was struck onto rich yeast
extract-peptone-dextrose (YPD) agar medium or yeast extract-peptone-glycerol (YPG) agar medium which have glucose or glycerol as the sole
carbon source, respectively. Isolate F produces small, transparent colonies on YPD and is unable to grow on YPG. Petite mutants have lost their
mitochondrial function, are unable to respire, and therefore unable to utilize non-fermentable carbon sources. Isolates were patched onto the plates
and photographed after incubation in the dark at 30uC for 24 hours. (B) The petite phenotype is not intrinsically involved in caspofungin (CF)
resistance of C. glabrata clinical isolates. Petite mutants were generated from early clinical isolate A by growth in 10 mg/ml ethidium bromide for
48 hours in the dark and were identified based on morphology and inability to grow on YPG. CF resistance was then compared to resistant petite
clinical isolate F in an MIC assay along with inhibition of Hsp90 with 20 mM geldanamycin (GdA) or inhibition of calcineurin with 10 mM cyclosporin A
(CsA). (C) CF-resistant petite mutants of C. glabrata are refractory to the synergy between caspofungin and inhibitors of Hsp90 or calcineurin. Petite
mutants were generated from late clinical isolate G as in part (B). CF resistance was then compared to the resistant petite clinical isolate F in an MIC
assay with or without pharmacological inhibition of Hsp90 with 20 mM GdA or pharmacological inhibition of calcineurin with 10 mM CsA. (D)C F
resistance of petite mutants of C. glabrata is dependent on calcineurin. Petite mutants were generated from the late clinical isolate G cnb1D deletion
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PLoS Pathogens | www.plospathogens.org 15 May 2012 | Volume 8 | Issue 5 | e1002718mutant as in part (B). Synergy between CF and Hsp90 inhibition with GdA (20 mM) or calcineurin inhibition with CsA (10 mM) was tested. MIC assays
were performed and analyzed as in Figure 1.
doi:10.1371/journal.ppat.1002718.g009
Figure 10. Fungal burden of the C. glabrata clinical isolate series and MET3p-HSP90 strain in a murine model of disseminated
infection. CD1 mice were infected with an inoculum of 2610
7 cells via lateral tail vein injection. One asterisk indicates P,0.05, two indicates P,0.01,
and three indicates P,0.001 (Kruskal-Wallis Test, Dunn’s Multiple Comparison). Fungal burden was measured in the (A) kidney and (B) spleen 7 days
post infection. Organs of mice infected with isolate F were sterile.
doi:10.1371/journal.ppat.1002718.g010
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glabrata strain, but was associated with a fitness cost with reduced
growth rate in the absence of drug (Figure 2). The fitness cost of
resistance was ameliorated with further evolution, based on
observations in vitro and in a murine model of systemic infection
(Figures 2 and 10). The 8 additional mutations in genes not
previously implicated in echinocandin resistance (Table 1) provide
candidates for novel resistance determinants as well as mutations
that mitigate the cost of resistance. Consistent with these
possibilities, increased dosage of CDC55, which acquired a
mutation accompanying the increase in fitness, mitigated the
fitness cost of the FKS2 mutation (Figure 3), while a mutation in
CDC6 that arose prior to the FKS2 mutation was sufficient to
confer a small increase in echinocandin resistance (Figure 5).
Further, we establish that Hsp90 governs both basal tolerance to
the echinocandins and bona fide resistance of clinical isolates
(Figure 6), and that Hsp90 is important for C. glabrata proliferation
in the mouse kidney (Figure 10). We found that calcineurin is a key
mediator of Hsp90-dependent resistance (Figures 7). Hsp90 and
calcineurin regulate echinocandin resistance by controlling
expression of the resistance determinant FKS2 (Figure 8), providing
a novel mechanism via which Hsp90 and calcineurin govern
echinocandin resistance in pathogenic fungi.
The whole genome sequence analysis yields powerful insights
into the evolutionary dynamics of adaptation in the host, as well as
novel mutations associated with resistance or with ameliorating the
fitness cost of resistance. To date, mechanisms of echinocandin
resistance remained restricted to mutations in the drug target. In
the C. glabrata series, mutations in 4 genes not previously associated
with echinocandin resistance (MOH1, GPH1, CDC6, and TCB1/2)
accompanied an early and small increase in echinocandin
resistance (Figure 1). Mutations in these genes could confer the
small increase in resistance, or could create a genetic background
in which the FKS2 mutation is less detrimental; in the latter case,
the mutation would have to confer a fitness benefit on its own in
order to be selected for in advance of the FKS2 mutation, or it
could be selectively neutral and fixed by genetic drift. Given that a
reduction in fitness accompanied the acquisition of these 4
mutations (Figure 2), it is likely that they contribute to resistance
or were fixed by genetic drift. Consistent with the former
possibility, polymorphisms in one of the genes that acquired a
mutation associated with the small increase in resistance, CDC6,
were common in an unrelated set of echinocandin-resistant C.
glabrata isolates with Fks2 S663P (Figure 4), and the CDC6-
A511G(K171E) mutation identified by whole genome sequencing
was sufficient to confer a small increase in resistance (Figure 5).
Mutations in 3 additional genes not previously implicated in
echinocandin resistance (DOT6, MRPL11, and SUI2) coincided
with the FKS2 mutation, and a last mutation in CDC55 arose in the
last isolate, without any associated change in resistance (Figure 1).
Given that the FKS2 mutation is sufficient for the full resistance
phenotype of the late clinical isolate (Figure 7), it is likely that these
other mutations are unrelated to echinocandin resistance or that
they mitigate the fitness cost of the FKS2 mutation. It is notable
that multiple mutations accumulated at the two major transitions
in resistance (Figure 1). This is consistent with strong selection
favouring the rapid accumulation of mutations in the lineage. That
each of the mutations identified persisted throughout the lineage is
consistent with the occurrence of selective sweeps, such that each
mutation rose to near fixation. Selective sweeps in response to
drug selection are also observed in experimental populations of C.
albicans during the evolution of azole resistance in vitro [107].
The fate of drug-resistant mutants in nature depends on their
fitness relative to drug-susceptible counterparts. While resistance
mutations are expected to confer a fitness benefit in the presence of
the drug, they may also confer a cost in terms of reduced fitness in
the absence of the drug. This model is consistent with the impact
of the FKS2 T1987C mutation observed in the C. glabrata lineage,
and reported for target-mediated echinocandin resistance in C.
albicans [88]. This mutation confers a major increase in growth in
the presence of echinocandin (Figure 2A), but also confers reduced
growth in the absence of the drug (Figure 2B). The deleterious
impact on fitness is likely due to the reduced catalytic capacity
commonly observed among 1,3-b-D-glucan synthase enzymes that
acquire amino acid substitutions that reduce their sensitivity to
echinocandins [36]. C. glabrata may upregulate FKS2 expression to
compensate for its decreased catalytic capacity [36], or may
acquire additional mutations that mitigate the cost of the
resistance mutation. The fitness effects of antibiotic resistance
mutations have been studied extensively in bacteria, where most
resistance mechanisms are associated with a fitness cost that
manifests in reduced growth rate [84]. In the vast majority of
cases, the fitness cost is mitigated by the acquisition of
compensatory mutations [84–87]. Consistent with these patterns,
any cost of resistance in experimental populations of C. albicans
that evolved azole resistance in vitro was mitigated was further
evolution [108], as many changes in gene expression observed in
the less fit, resistant population were restored to the ancestral state
[15]. In the C. glabrata lineage studied here, a mutation in CDC55
accompanied an increase in fitness of isolate G relative to isolate D
(Figures 1 and 2). Increased dosage of CDC55 ameliorated fitness
of an independent FKS2 T1987C mutant, independent of whether
it was the C463T(P155S) allele (Figure 3). This suggests that the
C463T(P155S) mutation may confer increased Cdc55 function
and that fitness can be ameliorated by either elevated activity or
dosage of Cdc55. This C463T(P155S) mutation was not identified
in other C. glabrata echinocandin-resistant FKS2 T1987C mutants
(Figure 4), suggesting that distinct compensatory mutations might
be favoured in vivo or that they may harbor duplications of CDC55.
The mechanisms by which alterations in CDC55 ameliorates
fitness of the FKS2 mutant and the scope of beneficial effects in
other backgrounds remains to be determined.
Morphological variants that emerge in an evolutionary lineage
can reveal important features of mechanisms of drug resistance or
drug synergy. Isolate F is a petite mutant based on morphology
and inability to grow on a non-fermentable carbon source
(Figure 9A). Such respiratory deficient mutants with loss of
mitochondrial function are associated with azole resistance in S.
cerevisiae, C. albicans, and C. glabrata [98–102]. The azole resistance
of petites is attributed to increased expression of multidrug
transporters of the ATP binding cassette family [98,99,101]. The
petite phenotype has not been linked to echinocandin resistance to
date, consistent with the limited evidence that multidrug
transporters are involved in resistance to this drug class [109–
112]. Indeed, induction of petite mutants in the early C. glabrata
clinical isolate A does not confer echinocandin resistance,
confirming that petite mutants are not intrinsically resistant to
echinocandins (Figure 9B). In S. cerevisiae, several mitochondrial
proteins have been identified as required for echinocandin
tolerance [113], consistent with the slight reduction in tolerance
we observe in C. glabrata petite mutant derivatives of isolate A
(Figure 9). A striking feature of the isolate F is that its echinocandin
resistance phenotype is recalcitrant to the impact of the Hsp90
inhibitor geldanamycin or calcineurin inhibitor cyclosporin A,
unlike that of all other isolates in the series (Figure 9C). Induction
of petite mutants in late clinical isolate G confirms that the petite
phenotype is intrinsically recalcitrant to the impact of geldana-
mycin or cyclosporin A (Figure 9C). Genetic compromise of
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resistance, suggesting that petites are simply resistant to cyclo-
sporin A (Figure 9D), and likely geldanamycin; this may be
attributable to overexpression of multidrug transporters in petites
that remove these inhibitors from the cell. Whether the original
isolate F petite mutant arose during evolution in the human host
or during sampling remains unknown, although our finding that
kidneys and spleens from mice infected with the petite mutant
were completely sterile (Figure 10), suggests that petite mutant
arose shortly before or during its isolation. In contrast, one C.
glabrata petite mutant was reported to have enhanced virulence
relative to an isolate recovered from the same patient at an earlier
time point, however, an isogenic control was lacking [102].
Consistent with our findings, most C. glabrata petite mutants have
been reported to have attenuated virulence relative to isogenic
controls [104].
Our findings of reduced kidney fungal burden in mice infected
with the late clinical isolate G with conditional expression of
HSP90 driven by the MET3 promoter support a role for Hsp90 in
proliferation in the host (Figure 10). That there was only a modest
reduction in fungal burden is surprising in light of Hsp90’s
essentiality in vitro, as observed by methionine-mediated transcrip-
tional repression (Figure 6 and 8). It is likely that methionine levels
in the mouse were not sufficient to repress the C. glabrata MET3
promoter and deplete Hsp90, and that methionine levels were
even lower in the spleen, leading to no significant differences in
fungal burden (Figure 10). Notably, methionine levels in the mouse
were sufficient to cause avirulence of an ino1D/ino1D itr1D/
MET3p-ITR1 conditional mutant of C. albicans [105], but only
partial attenuation of virulence of a C. albicans conditional mutant
of the essential gene FBR1 (fbr1D/MET3p-FBR1) [114]. The
impact on virulence using the MET3 system to deplete essential
genes may depend on the level of depletion required to observe
phenotypic effects. Using a tetracycline-repressible promoter
system and delivery of tetracycline to the mice in a systemic
model of infection, Hsp90 has been shown to be required for
proliferation of C. albicans [106], suggesting that this promoter
system may be more suitable for in vivo studies given that doses of
tetracycline can be titrated.
Our results further establish Hsp90 and calcineurin as the first
regulators of bona fide echinocandin resistance in C. glabrata, and
reveal that resistance circuitry has been rewired over evolutionary
time. The molecular chaperone Hsp90 and its client protein
calcineurin govern basal tolerance and resistance to both the
azoles and the echinocandins in C. albicans [41,44,47]. Pharma-
cological inhibition of Hsp90 can enhance the efficacy of azoles
against C. glabrata [115], and calcineurin plays an important role in
both azole and echinocandin tolerance [49]. The roles of Hsp90
and calcineurin in azole resistance are conserved in S. cerevisiae
[44,47]. However, compromise of Hsp90 or calcineurin function
does not alter echinocandin susceptibility in S. cerevisiae under any
of the standard conditions tested where echinocandin susceptibility
of C. albicans is affected [41]. Here, we find that Hsp90 and
calcineurin are required for basal tolerance to echinocandins in C.
glabrata as well as for resistance that evolves in a human host
(Figures 4 and 5), suggesting that despite the closer evolutionary
relationship of C. glabrata to S. cerevisiae, the C. glabrata cellular
circuitry governing resistance to drugs that target the cell wall
shares more similarity to that of its more distant pathogenic
relative, C. albicans. While conditions may exist in which Hsp90
and calcineurin influence echinocandin susceptibility in S. cerevisiae,
it is clear that the C. glabrata phenotypic response more closely
resembles that of C. albicans than S. cerevisiae. Notably, signaling
pathways governing cell wall integrity have been rewired between
C. albicans and S. cerevisiae [116]. The cell wall is essential for fungal
viability and is an elaborate structure, components of which are
recognized by vigilant immune cells in the human host [117]. As
commensals and opportunistic pathogens, C. glabrata and C.
albicans are likely to harbour circuitry governing cell wall
architecture that is subject to strong selection in response to host
immune system challenge.
This work establishes that targeting Hsp90 or calcineurin has
broad therapeutic potential for infections caused by one of the
leading fungal pathogens of humans, and complements the
expanding repertoire of therapeutic applications for inhibitors of
Hsp90 and calcineurin in the treatment of infectious disease.
Inhibition of Hsp90 or calcineurin transforms echinocandins from
ineffective to highly efficacious against echinocandin-resistant C.
glabrata (Figures 6 and 7). Notably, a human recombinant antibody
against Hsp90 also has synergistic activity with echinocandins
against C. glabrata in a mouse model [118], though the mechanism
by which this antibody works remains entirely unknown as it is
unlikely to enter intact fungal cells to influence function of the
cytosolic Hsp90 chaperone. Genetic compromise of Hsp90
function enhances the efficacy of azoles and echinocandins in a
mouse model of systemic C. albicans infection [41,45]. Genetic or
pharmacological compromise of Hsp90 also transforms flucona-
zole from ineffective to highly efficacious against C. albicans
biofilms in a mammalian model of biofilm infection [119]. Beyond
Candida species, inhibition of Hsp90 also enhances antifungal
efficacy against the most lethal mould, A. fumigatus, in biofilms and
in a metazoan model of infection [45,119]. Consistent with the
functional relationship between Hsp90 and calcineurin, calci-
neurin inhibitors also have therapeutic potential and are
synergistic with azoles against C. albicans endocarditis, keratitis,
and biofilms in mammalian models [120–122]. Beyond their
utility in the treatment of fungal infections, Hsp90 and calcineurin
are promising targets for treating infections caused by protozoan
parasites including Plasmodium falciparum, Trypanosoma evansi, and
Leishmania major [123–126]. Supporting their clinical relevance,
Hsp90 inhibitors have advanced in clinical trials for the treatment
of cancer and other diseases [9,127,128], and calcineurin
inhibitors are widely used in the clinic as immunosuppressants
[92]. Given the potential for toxicity upon inhibition of key cellular
regulators in the host during infection [45], the challenge for
further development of Hsp90 and calcineurin as therapeutic
targets for infectious disease lies in developing pathogen-selective
inhibitors or drugs that target pathogen-specific components of the
cellular circuitry governing drug resistance and virulence.
Materials and Methods
Ethics statement
Dr. Susan M. Poutanen discussed this study and specifically
highlighted the inclusion of the case history and the case isolates in
this study with Nushrat Sultana, Research Ethics Board Coordi-
nator for the Research Ethics Board at Mount Sinai Hospital in
Toronto, Canada, the hospital in which the case patient had been
hospitalized. Nushrat Sultana confirmed that completing and
publishing a case study that involves only a single case does not
require review by the Research Ethics Board. Written confirma-
tion has been provided by Dr. Ronald Heslegrave, Chair,
Research Ethics Board, Mount Sinai Hospital. Oral and written
consent was provided by the case patient’s mother, as the patient is
deceased. Animals studies conducted in the Division of Laboratory
Animal Resources (DLAR) facilities at Duke University Medical
Center (DUMC) were handled with good practice as defined by
the United States Animal Welfare Act and in full compliance with
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Committee (IACUC). The murine systemic infection model was
reviewed and approved by the DUMC IACUC under protocol
number A238-09-08.
Patient history for C. glabrata clinical isolate series
A 43 year-old female had four episodes of Candida glabrata
candidemia between April 2004 and October 2005. Her past
medical history was significant for severe fistulizing Crohn’s
disease diagnosed at the age of 9 years. She had been on total
parenteral nutrition (TPN) since 2003 for short gut syndrome due
to numerous small bowel resections over the 30-year course of her
disease.
April 2004. The patient was admitted to hospital with
generalized malaise, fever, and Clostridium difficile infection
associated diarrhea (CDAD). Admission blood cultures demon-
strated C. glabrata candidemia with evidence of pulmonary nodules
on thorax computerized tomography (CT). No evidence of
endophthalmitis was noted on ophthalmologic exam. Her two
central venous catheters were removed and caspofungin was
started at 70 mg od61 then 50 mg od intravenously with clinical
response. Cultures of the catheter tip and a repeat set of blood
cultures were negative. After 3 weeks of treatment, she was
discharged with plans to continue caspofungin until resolution of
the pulmonary nodule on repeat thorax CT. An outpatient
echocardiogram was also ordered. The patient was non-adherent
with outpatient follow-up but had three sets of negative blood
cultures drawn while off caspofungin therapy during emergency
department visits 6 months after discharge.
January 2005. The patient presented to the hospital with a 1-
week history of fatigue, nausea, vomiting and diarrhea, and was
diagnosed with TPN-associated cholestasis. Three out of four sets
of blood cultures drawn at admission grew C. glabrata. Eye exams
revealed no evidence of endophthalmitis. Her central venous
catheter was removed and she was restarted on caspofungin at the
same dose. Four sets of repeat blood cultures were negative. She
continued to have intermittent fevers and one week after
admission was transferred to the intensive care unit with septic
shock and intubated for hypoxic respiratory distress. A thorax CT
demonstrated bilateral airspace consolidation consistent with acute
respiratory distress syndrome and an abdominal CT demonstrated
a fistulous tract to a 5 cm60.3 cm anterior abdominal wall
collection. The patient was treated with piperacillin-tazobactam
with an excellent clinical response. Piperacillin-tazobactam was
ordered to continue until the collection resolved. Caspofungin was
stopped two weeks after the last positive culture for C. glabrata.
February 2005. One week after the caspofungin was stopped
while continuing on piperacillin-tazobactam, the patient presented
with recrudescence of fever and abdominal pain. Five out of five
sets of blood cultures grew C. glabrata. Eye exam and transthoracic
echocardiogram revealed no evidence of endophthalmitis or
endocarditis. Her central venous catheter was removed and the
catheter tip was positive for Candida species, not C. albicans.
Caspofungin was restarted at the same dose with good clinical
response. Two sets of repeat blood cultures were negative.
Caspofungin was continued for a total of 4 weeks and the patient
was discharged. The patient was not adherent to outpatient follow-
up appointments but multiple repeat blood cultures drawn at the
TPN clinic over the following six months off caspofungin were
negative.
October 2005. The patient presented to the emergency
department with a lower gastrointestinal bleed and shock and was
immediately transferred to the intensive care unit. She was
empirically started on piperacillin-tazobactam and fluconazole for
presumed intra-abdominal sepsis but died 3 days after admission.
Three sets of ante-mortem blood cultures grew C. glabrata.
Strains and culture conditions
Archives of C. glabrata strains were maintained at 280uC in 25%
glycerol. Strains were grown in either YPD (1% yeast extract, 2%
bactopeptone, 2% gucose), YPG (1% yeast extract, 2% bacto-
peptone, 2% glycerol), synthetic defined medium (0.67% yeast
nitrogen base, 2% glucose) supplemented with required amino
acids, or RPMI medium 1640 (Gibco, 3.5% MOPS, 2% glucose,
pH 7.0). 2% agar was added for solid media. Strains used in this
study are listed in Table S2. Strain construction is described in
Text S1.
Plasmid construction
Recombinant DNA procedures were performed according to
standard protocols. Plasmids used in this study are listed in Table
S3. Plasmid construction is described in the Text S1. Plasmids
were sequenced to verify the absence of any nonsynonymous
mutations. Primers used in this study are listed in Table S4.
Pulsed-field Gel Electrophoresis (PFGE) karyotyping and
restriction enzyme-PFGE
PFGE-karyotyping and restriction enzyme-PFGE using SfiI
were performed following previously reported methods [129].
Whole genome sequencing
Genomic DNA was extracted from clinical isolate A and G, and
sequencing libraries were prepared using the Illumina genomic
DNA library preparation kit according to the manufacturers
recommendations (Illumina, CA) with several modifications. In
brief, DNA was sheared by sonication to an average fragment
length of 200 base pairs. Illumina adapters were blunt-end ligated
and libraries were amplified by PCR and purified using Ampure
(Agencourt) beads at a DNA:bead ratio of 1:0.9. Each sample was
sequenced together in a single lane on an Illumina Genome
Analyzer II platform, yielding 5.1 and 3.8 million 76 base pair
single-end reads for isolate A and isolate G, respectively, resulting
in 22 to 306genome coverage. Reads were aligned using SOAP2
(PMID: 19497933) against the reference genome sequence of
CBS138 [57]. Single nucleotide variants were identified using a
machine learning approach as described previously [130]. All non-
synonymous mutations identified were validated independently
using Sanger sequencing. Raw data is available for download from
the Short Read Archive under accession SRA047280.2.
Mutation mapping
The 9 non-synonymous mutations identified by whole genome
sequencing were mapped across clinical isolates B, C, D, E, and F
using Sanger sequencing. CgFKS2 was amplified using oLC1344/
1345, CgDOT6 with oLC1559/1560, CgMOH1 with oLC1561/
1562, CgGPH1 with oLC1563/1564, CgMRPL11 with oLC1565/
1566, CgCDC6 with oLC1567/1568, CgCDC55 with oLC1569/
1570, CgSUI2 with oLC1571/1572, and CgTCB1/2 with
oLC1573/1574. CgFKS2 was sequenced with oLC1344, CgDOT6
with oLC1559, CgMOH1 with oLC1561, CgGPH1 with oLC1563,
CgMRPL11 with oLC1565, CgCDC6 with oLC1567, CgCDC55
with oLC1569, CgSUI2 with oLC1571, and CgTCB1/2 with
oLC1573.
Minimum inhibitory concentration assays
Antifungal susceptibility was determined in flat bottom, 96-well
microtiter plates (Sarstedt) using a modified broth microdilution
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(MIC) tests were set up in a total volume of 0.2 ml/well with 2-fold
dilutions of caspofungin (CF, generously provided by Rochelle
Bagatell). Echinocandin gradients were from 16 mg/ml down to 0
with the following concentration steps in mg/ml: 16, 8, 4, 2, 1, 0.5,
0.25, 0.125, 0.0625, 0.03125, 0.015625, and 0. Cell densities of
overnight cultures were determined and dilutions were prepared
such that ,10
3 cells were inoculated into each well. Geldanamy-
cin (GdA, A.G. Scientific, Inc.) and radicicol (RAD, A.G.
Scientific, Inc.) were used to inhibit Hsp90 at the indicated
concentrations, and cyclosporin A (CsA, CalBiochem) and FK506
(A.G. Scientific, Inc.) were used to inhibit calcineurin at the
indicated concentrations. Dimethyl sulfoxide (DMSO, Sigma
Aldrich Co.) was the vehicle for GdA, RAD, CsA, and FK506.
Sterile water was the vehicle for CF. Plates were incubated in the
dark at 30uC for the time period indicated, at which point plates
were sealed and re-suspended by agitation. Absorbance was
determined at 600 nm using a spectrophotometer (Molecular
Devices) and was corrected for background from the correspond-
ing medium. Each strain was tested in duplicate on at least two
occasions. MIC data was quantitatively displayed with colour
using the program Java TreeView 1.1.3 (http://jtreeview.
sourceforge.net).
Clinical antifungal MICs were determined using broth micro-
dilution with RPMI 1640 broth for amphotericin, fluconazole,
ketoconazole, itraconazole, voriconazole, and caspofungin follow-
ing Clinical and Laboratory Standards Institute document M27-
A3 [56]. Visual MIC endpoints were read after 24 hours of
incubation at 35uC for caspofungin and after 48 hours of
incubation for all other drugs. Complete inhibition was used to
determine amphotericin endpoints; 50% inhibition (compared to
growth control) was used for caspofungin and 80% inhibition was
used for the other drugs.
Quantitative reverse transcription PCR (qRT-PCR)
To measure gene expression changes in response to caspofungin
treatment in C. glabrata, cells were grown overnight in YPD at
30uC. Cells were diluted to OD600 of 0.2 in SD and grown for
2 hours in duplicate for each strain at 25uC. After 2 hours of
growth 120 ng/ml CF was added to one of the two duplicate
cultures and left to grow for one additional hour at 25uC. Cells
were centrifuged and pellets were frozen at 280uC immediately.
RNA was isolated using the QIAGEN RNeasy kit and RNAse-free
DNase (QIAGEN), and cDNA synthesis was performed using the
AffinityScript cDNA synthesis kit (Stratagene). PCR was per-
formed using SYBR Green JumpStart Taq ReadyMix (Sigma-
Aldrich Co) with the following cycling conditions: 94uC for
2 minutes, 94uC for 15 seconds, 60uC for 1 minute, 72uC for
1 minute, for 40 cycles. All reactions were performed in triplicate,
using primers for the following genes: CgACT1 (oLC1500/1501),
CgCNB1 (oLC1502/1503), and CgFKS2 (oLC1498/1499). Data
were analyzed using iQ5 Optical System Software Version 2.0
(Bio-Rad Laboratories, Inc). Statistical significance was evaluated
using GraphPad Prism 5.0.
To monitor gene expression changes in response to reduction of
HSP90 levels, strains CgLC751 and CgLC2121 were grown
overnight at 30uC in synthetic defined medium supplemented with
0.25 mg/ml methionine. Stationary phase cultures were diluted to
an OD600 of 0.2 and grown for 2 hours at 30uC in synthetic
defined medium with methionine. Following incubation, cultures
were split and 120 ng/ml caspofungin added to one set. Cells were
harvested after one hour and RNA was isolated using the
QIAGEN RNeasy kit and cDNA synthesis was performed using
the AffinityScript cDNA synthesis kit (Stratagene). PCR was
carried out using the SYBR Green Fast Mix (Applied Biosystems)
with the following cycle conditions: 95uC for 20 seconds, and
95uC for 3 seconds, 60uC for 30 seconds, for 40 cycles. All
reactions were done in triplicate using the following primer pairs:
CgACT1 (oLC1500/1501), CgHSP90 (oLC2155/2156), CgFKS2
(oLC1498/1499). Data were analyzed in the StepOne analysis
software (Applied Biosystems).
Growth curves
Growth kinetics were measured in C. glabrata strains by
inoculating cells from an overnight culture grown in YPD at
30uCt oa nO D 600 of 0.0625 in 100 ml of RPMI with 2% glucose
in flat bottom, 96-well microtiter plates (Sarstedt). Cells were
grown in a Tecan GENios microplate reader (Tecan Systems Inc.,
San Jose, USA) at 37uC with orbital shaking. Optical density
measurements (OD600) were taken every 15 minutes for 48 hours.
Statistical significance was evaluated using GraphPad Prism 4.0.
For assays involving plasmids, selection was maintained with
150 mg/ml nourseothricin (Werner BioAgents).
Generation of petite mutants of C. glabrata
C. glabrata strains were inoculated from solid YPD medium to
liquid YPD medium containing 10 mg/ml ethidium bromide
(EtBr). The culture was grown overnight, shaking at 30uC in the
dark. Approximately 100 cells were plated on YPD agar to isolate
single colonies. After 2 days of incubation at 30uC, single colonies
were tested for growth on YPD agar and YP-glycerol agar.
Colonies able to grow on glucose as the sole carbon source but not
on glycerol as the sole carbon source were selected.
Murine model of systemic infection
Four- to five-week-old male CD1 mice from The Jackson
Laboratory (n=10 for each group) were utilized in this study. C.
glabrata strains were grown in 10 ml liquid methionine-free
minimal medium (6.7 g yeast nitrogen base without amino acids
and 20 g glucose in 1 liter) overnight at 30uC. Cultures were
washed twice with 10 ml of phosphate buffered saline (PBS), and
the cells were then resuspended in 2 ml of PBS. Cells were
counted with a hemocytometer and resuspended in an appropriate
amount of PBS to obtain an infection inocula concentration of
1610
8 cells/ml. Two hundred microliters (2610
7 cells) were used
to infect mice by lateral tail vein injection. Appropriate dilutions of
the cells were plated onto solid methionine-free minimal medium
and incubated at room temperature for 48–96 hours to confirm
cell viability. C. glabrata infected mice were sacrificed and dissected
on day 7 post-infection. The kidney and spleen tissues were
removed, weighed, transferred to a 15 ml Falcon tube filled with
5 ml PBS, and homogenized for 10 seconds at 17,500 rpm (Power
Gen 500, Fisher Scientific). Tissue homogenates were serially
diluted, and 100 ml was plated onto YPD solid medium (except
CgLC2121 and CgLC2122 strains which were plated onto
methionine-free minimal medium containing 100 mg/ml chlor-
amphenicol). The plates were incubated at room temperature for
48–96 hours to determine CFUs per gram of organ. We
confirmed that organ-recovered CgLC2121 and CgLC2122 cells
only grew on methionine-free minimal medium but not on
medium containing methionine. All experimental procedures were
carried out according to NIH guidelines and Duke IACUC
protocols for the ethical treatment of animals.
Accession numbers (NCBI Entrez Gene ID number)
C. glabrata: ACT1 (2890423); CDC55 (2890752); CDC6
(2890231); CNB1 (2890566); DOT6 (2886442); FKS1 (2888318);
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(2891108); MET3 (2886500); MOH1 (2887590); MRPL11
(2889720); RHO1 (2888920); SUI2 (2886561); TCB1/2 (2889714).
S. cerevisiae: CDC55 (852685); DOT6 (856822); FKS1 (851055);
FKS2 (852920); FKS3 (855353); GPH1 (856289); MOH1 (852231);
MRPL11 (851325); RHO1 (856294); SUI2 (853463); TCB1
(854253); TCB2 (855637).
Supporting Information
Figure S1 C. glabrata clinical isolates serially isolated
from a patient are of the same lineage. Pulsed-field gel
electrophoresis (PFGE) karyotype analysis reveals that isolates A
through G, inclusive, are related and likely of the same lineage. All
samples were run on the same gel and the picture was cropped to
order the isolates. Lanes ‘M’ contain a marker, lanes 1 and 2 are of
two control C. glabrata strains and lanes A through G are of isolate
A through isolate G, in the same order.
(TIF)
Figure S2 Hsp90 and calcineurin play critical roles in
echinocandin resistance of C. glabrata in RPMI medi-
um. Pharmacological inhibition of Hsp90 with geldanamycin
(GdA) or pharmacological inhibition of calcineurin with cyclo-
sporin A (CsA) reduces caspofungin (CF) resistance of C. glabrata
clinical isolates in an MIC assay. Isolates are arranged in the same
order as they were recovered from a patient who was on CF
treatment, where isolate A was recovered pre-treatment and
isolate G was recovered after multiple rounds of CF treatment.
Assays were done in RPMI medium supplemented with 2%
glucose at 30uC for 72 hours. Optical densities were averaged for
duplicate measurements and normalized relative to CF-free
controls.
(TIF)
Table S1 In Vitro susceptibility of C. glabrata clinical
isolates to clinically relevant antifungal drugs. Antifungal
minimum inhibitory concentrations (MICs) for serially isolated C.
glabrata clinical isolates were determined using broth microdilution
with RPMI 1640 broth for amphotericin, fluconazole, ketocona-
zole, itraconazole, voriconazole, and caspofungin following
Clinical and Laboratory Standards Institute document M27-A3.
Isolates are arranged in the same order as they were recovered
from the patient, where isolate A was recovered pre-treatment and
isolate G was recovered after multiple rounds of caspofungin
treatment. MIC endpoints (mg/ml) were read after 24 hours of
incubation at 35uC for caspofungin and after 48 hours of
incubation for all other drugs. Complete inhibition was used to
determine amphotericin endpoints; 50% inhibition (compared to a
drug-free growth control) was used for caspofungin and 80%
inhibition was used for other drugs.
(DOC)
Table S2 Candida glabrata strains used in this study.
(DOC)
Table S3 Plasmids used in this study.
(DOC)
Table S4 Primers used in this study.
(DOC)
Text S1 Supporting Materials and Methods.
(DOC)
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